Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Curr Opin Biotechnol. 2019 Mar 1;60:138–145. doi: 10.1016/j.copbio.2019.01.010

Figure 3.

Figure 3.

Delivery of TLR7/8a (R848) in cyclodextrin NPs (CDNPs) enhances tumor therapy in the MC38 colon adenocarcinoma mouse model. (a) Scheme to assemble R848 in CDNPs (CDNP-R848). Treatment of mice with CDNP-R848 (b) reduces tumor area, (c) improves survival, and (d) reduces overall tumor burden relative to free R848. Adapted with permission from [11].